reports
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced ...
Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwideAware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing...
Biomerica provides update on inFoods® IBS expansion
Biomerica provides update on inFoods® IBS expansion - Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas. - Average quarterly increase in physicians prescribing inFoods more than doubled each quarter over the past 12 months. - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product. - Company receives notice of allowance for five new patents in Europe, Canada and Japan; the inFoods technology now has 25 Issued/allowed patents. IRVINE, Calif., April...
Biomerica Reports Third Quarter 2024 Financial Results
Biomerica Reports Third Quarter 2024 Financial Results Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference in the DDW Irritable Bowel Syndrome (IBS) Clinical Session Company in discussions with Key Clinical Lab Customers for Use of its Recently US FDA 510(k) Cleared Hp Detect™ Test Product, Designed to Detect the Presence of the H. pylori Bacteria that infects approximately 35% of th...
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive D...
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference Collaborators at the University of Michigan will present new Data on InFoods® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company at the forefront of innovative gastroenterology solutions, proudly announces that data from collaborators at the University of Michigan utilizing its groundbreaking inFoods IBS technologies will be presented in the IBS Clinical Sessio...
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic...
Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, proudly announces the appointment of Gary Huff to its Strategic Advisory Board (SAB). Mr. Huff, former CEO of Diagnostics at Laboratory Corporation of America Holdings, “LabCor...
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Bo...
Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built and ultimately managed the sale of the company for $1.53 billion IRVINE, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Jack Kenny, former CEO and board membe...
Biomerica Reports Second Quarter 2024 Financial Results
Biomerica Reports Second Quarter 2024 Financial Results Revenues excluding Covid test sales increased 10.3% for the second fiscal quarter of 2024 vs the second fiscal quarter of 2023.Loss per shares narrows to $0.09 per share from $0.12 per share reflecting disciplined operating expense management.Company Received US FDA 510(k) Clearance for Its Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects approximately 35% of the U.S. Population. IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”)...
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA ...
Biomerica Received US FDA 510(k) Clearance for Their Hp Detect™ ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population Over 80% of gastric cancers are attributed to H. pylori bacterial infection Gastric cancer is the third most common cause of cancer related death in the world H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of ad...
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conf...
Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16 IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings. About Biomerica (NASDA...
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Gr...
Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups Biomerica remains on track for inFoods® IBS national rollout during calendar 2024, and expects strong product revenue growth during national rolloutVeteran Vice President of Sales and National Accounts hired along with first set of regional sales representatives IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that several new Gastrointestinal (GI) groups have signed up and begun using the Company's revo...
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
REPEAT - Biomerica Reports First Quarter 2024 Financial Results Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP gross margin percentage of 24.1% for the first fiscal quarter of 2024 improved substantially over -3.4% for the first fiscal quarter of 2023 Company completes pre-launch phase for inFoods IBS; veteran Vice President of sales and national accounts hired along with r...
Biomerica Reports First Quarter 2024 Financial Results
Biomerica Reports First Quarter 2024 Financial Results Revenues excluding Covid test sales increased 16.3% for first fiscal quarter of 2024 vs the first fiscal quarter of 2023 Company believes current cash position, forecasted revenue growth and corporate strategy is expected to enable it to achieve profitability GAAP gross margin percentage of 24.1% for the first fiscal quarter of 2024 improved substantially over -3.4% for the first fiscal quarter of 2023 Company completes pre-launch phase for inFoods IBS; veteran Vice President of sales and national accounts hired along with regional k...
Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Det...
Dubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening Test Simple 2 minute at-home test detects an early warning sign of colorectal cancer, the third most common cancer worldwide IRVINE, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that the Dubai government has officially approved insurance reimbursement for the EZ Detect colorectal disease at-home screening test, which is designed to detect an early warning sign of colorectal cancer and other colorectal diseases. Colorectal ca...
Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Dire...
Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors Kenny has proven track record of driving growth at companies within the healthcare space and holds significant management and public company board experience, most recently as CEO of Meridian BioscienceAs CEO Kenny managed the sale of Meridian Biosciences in an all-cash transaction valued at approximately $1.53 billion NEWPORT BEACH, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the app...
Biomerica Reports Fiscal 2023 Year End Results
Biomerica Reports Fiscal 2023 Year End Results Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US inFoods IBS completes pre-launch phase; Veteran VP of sales and national accounts hired; On track for national launch by calendar Q1 2024 IRVINE, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: ), (the “Company”) a global provider of advanced medical products, today reported its fiscal 2023 financial results. Net sales for t...
CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect...
CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect™ Colorectal Disease Screening Test Over 7,000 CVS Pharmacy Stores to sell the EZ Detect™ TestSimple 2 minute at-home test detects an early warning sign of colorectal cancer IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that CVS Pharmacy has begun in-store sales rollout of the Company’s EZ Detect™ colorectal disease screening test in over 7,000 stores nationwide throughout the CVS Pharmacy retail system. Biomerica has shipped the EZ Detect product to ...
Biomerica Receives Notice of Patent Allowance in China for a Potential...
Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients Patent Claims Describe a Novel System to Predict and Help Prevent Adverse Food Reactions Using Personal Medical DataThe Patent further describes Algorithms to help Determine Safety Levels of Food Ingredients, Offering a Personalized Approach to Dietary Interventions and Safety IRVINE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a...
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole...
inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology Gastro Health, a leading gastroenterology group, plans to utilize this simplified blood collection method when recommending the inFoods® IBS to their patients Biomerica also announced that inFoods® IBS clinical trial data was presented at the DDW conference May 8th.The data showed that the inFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API)inFoods IBS showed improvement in API similar to, and in some cases better than, current IB...
Biomerica’s inFoods® IBS test is now available at Gastro Health, provi...
Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS). Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: ), (the “Company”) a global provider of advanced medical diagn...
Biomerica Reports Q3 Fiscal 2023 Results
Biomerica Reports Q3 Fiscal 2023 Results For the nine months ended February 28, 2023 vs. the same period in 2022, revenues, excluding sales of Covid-related products, increased by 16%.InFoods® IBS Laboratory Developed Test (LDT) validation testing at the CLIA Lab has been completed, patient testing now underway. IRVINE, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced its fiscal third quarter and nine month results ended February 28, 2023. For the nine months ended Februa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.